GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AutoSynVax overview

AutoSynVax is under development for the treatment of solid tumors including melanoma, non-small cell lung cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, head and neck cancer, cervical cancer, and soft tissue sarcoma. The therapeutic candidate is administered through subcutaneous route. The therapeutic candidate constitutes synthetic peptide neoantigens complexed with heat shock proteins (Hsp70) that shuttle neoantigens to antigen presenting cells. It targets cancer neoantigens with an autologous synthetic vaccine approach.

Agenus overview

Agenus is a clinical-stage immuno-oncology company that discovers, develops, and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company collaborates with several pharmaceutical companies such as GSK, Incyte, and Merck. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

For a complete picture of AutoSynVax’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.